Latest news and press releases about PureTech Health plc (PRTC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others.
Price
| Price | $17.38 |
| Market Cap | $4.2B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.13 |
| EV / EBITDA | -42.07 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -31.83% |
| Return on Invested Capital | -19.64% |
| Return on Assets | -20.48% |
| Gross Margin | -471.15% |
| Operating Margin | -2115.41% |
| Net Margin | -2355.50% |
Related companies: CLYM · GNTA · INBX · IVA · KROS · SLN · TARS
Explore sector: Healthcare · Biotechnology
More sections of PRTC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks